Nuveen Impact Bond ETF
NUIB · ETF
About NUIB
- Issuer
- Nuveen
- Expense ratio
- 0.37%
- Assets under management
- $51.72M
- Inception
- Sep 14, 2026
- Asset class
- Fixed Income
- Website
- nuveen.com
NUIB key statistics
- Price-earnings ratio
- 0.00
- Average volume
- 3.59K
- Volume
- 7
- Open price
- $25.10
- High today
- $25.10
- Low today
- $25.10
- 52 Week high
- $25.15
- 52 Week low
- $24.66
Nuveen Impact Bond ETF (NUIB) at a glance
As of Oct 23, 2026, Nuveen Impact Bond ETF (NUIB) shares are priced at $25.10, giving the company a price-to-earnings ratio of 0.00.
Volume so far is 7 shares, below the average of 3.59K shares a day.
Over the past year Nuveen Impact Bond ETF has ranged from $24.66 to $25.15, and now sits 89% of the way up that range.
Most active stocks
Highest trading volume today
- EARIEntertainment Arts Research$0.0002+0.00%
- GTVHGolden Triangle Ventures$0.0002+100.00%
- TMSHTrans Global Assets$0.0003+20.00%
- RDARRaadr$0.0002+0.00%
- GPUSHyperscale Data$0.1689+34.05%
- SEIISharing Economy International$0.0002−33.33%
- ELMEElme Communities$1.77+0.57%
- SHFSSHF Holdings$0.1324−61.39%
- XXII22nd Century Group$0.1977−8.34%
- NBNDNetBrands$0.0006−40.00%
- NVDGraniteShares ETF Trust$4.19+0.96%
- HIRUHiru$0.0006+9.09%
Newly listed
Companies that went public in the past six weeks
- TCXBTCGX Acquisition Corp. II$10.49−0.10%
- CTYCITY THERAPEUTICS$20.77+0.00%
- IAMIambic Therapeutics$14.26−2.79%
- AMROAmaero$5.84+7.75%
- FLSCFrazier Life Sciences Acquisition Corp. II$10.30+0.29%
- TRXBTRex Bio$13.81−10.90%
- RTSNRetension Pharmaceuticals$15.25−1.61%
- PAXGUPine Tree Acquisition$10.01+0.05%
- PORTUSouthport Acquisition Corp. IIListed Oct 1, 2026
- CHWMChilwa Minerals$5.13−0.77%
- ACCVAccelevation Holdings$12.38+1.06%
- RZAIROZE AI$10.92−1.89%
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.